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ABSTRACT 20 
Staphylococcus aureus is an opportunistic human pathogen and a major cause of invasive 21 
infections such as bacteremia, endocarditis, pneumonia and wound infections. FhuD2 is a 22 
staphylococcal lipoprotein involved in the uptake of iron-hydroxymate and is under the control 23 
of the iron uptake regulator Fur. The protein is part of an investigational multi-component 24 
vaccine formulation that has shown protective efficacy in several murine models of infection. 25 
Even though fhuD2 expression was shown to be upregulated in murine kidneys infected with 26 
S. aureus, it is unknown whether the bacterium undergoes increased iron deprivation during 27 
prolonged infection. Furthermore, different infection niches of S. aureus might provide 28 
different environments and iron availability resulting in different fhuD2 expression pattern 29 
within different host organs. To address these questions, we characterized the in vitro 30 
expression of the fhuD2 gene and confirmed Fur-dependent iron-regulation of its expression. 31 
We further investigated its expression in mice infected with a bioluminescent reporter strain of 32 
S. aureus expressing the luciferase operon under the control of the fhuD2 promoter. The 33 
emission of bioluminescence in different organs was followed over a seven-day time course, 34 
as well as quantitative real-time PCR analysis of the RNA transcribed from the endogenous 35 
fhuD2 gene. Using this approach, we could show that fhuD2 expression was induced during 36 
infection in all organs analyzed and that differences in expression were observed in the 37 
temporal expression profiles, and between infected organs. Our data suggest that S. aureus 38 
undergoes increased iron deprivation during progression of infection in diverse host organs 39 
and accordingly induces dedicated iron acquisition mechanisms. Since FhuD2 plays a central 40 
role in providing the pathogen with the required iron, further knowledge of the patterns of 41 
fhuD2 expression in vivo during infection is instrumental in better defining the role of this 42 
antigen in S. aureus pathogenesis and as a vaccine antigen.   43 
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INTRODUCTION 44 
Staphylococcus aureus is a Gram-positive pathogen commonly isolated within the hospital 45 
environment (1). S. aureus is part of the normal flora of the skin and nares and it is estimated 46 
that up to 30% of the human population are long-term asymptomatic carriers of the bacterium 47 
(2). S. aureus can cause a wide range of disease manifestations ranging from suppurative 48 
and subcutaneous skin infections to severe and systemic infections such as pneumonia, 49 
sepsis, septic arthritis, endocarditis and osteomyelitis (3, 4). Infections can become persistent 50 
as the bacterium disseminates throughout the host causing abscess formation (5). 51 
Progression to disease is often opportunistic and affects both immunocompromised and 52 
immunocompetent patients. S. aureus was the cause of over 80,000 severe MRSA infections 53 
resulting in more than 11,000 deaths in 2011 in the US alone reaching a death toll 54 
comparable to that of HIV (6).  55 
The capacity of S. aureus to cause a wide spectrum of human disease reflects its ability to 56 
adapt to distinct microenvironments in the human body. The pathogenesis of S. aureus 57 
infection is a complex process involving a tight regulation of numerous virulence factors. 58 
S. aureus presents heterogeneity through variability in gene and protein expression in 59 
response to environmental factors (7).  60 
Iron is of key importance for the metabolism of S. aureus as it acts as a cofactor for numerous 61 
proteins involved in central metabolism and respiration. Upon encountering iron limiting 62 
conditions, S. aureus up-regulates dedicated iron uptake systems as well as glycolysis and 63 
down-regulates the tricarboxylic acid (TCA) cycle. Under extreme iron limitation the electron 64 
transfer chain is inactivated and the bacterium survives under fermentative growth (8). The 65 
TCA cycle involves numerous enzymes that require iron as a cofactor (9). Glycolysis 66 
generates ATP independently of respiration resulting in the accumulation of pyruvate and 67 
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lactate. Lactate was shown to be secreted by iron-starved S. aureus, resulting in acidification 68 
of the surrounding medium. It was suggested that this acidification might contribute to the 69 
liberation of iron from the host sequestration proteins transferrin and lactoferrin (8). 70 
Iron availability is severely limited during infection and the ability of S. aureus to sequester 71 
iron from the host significantly influences its pathogenesis. Expression of iron-regulated 72 
genes is under the control of the ferric iron uptake regulator Fur. In S. aureus Fur also 73 
indirectly contributes to coordinated repression of secreted hemolysins and cytotoxins. Under 74 
iron limiting conditions, Fur repression is relieved and up-regulation of these factors occurs. 75 
On the other hand, Fur contributes positively to the expression of immunomodulatory proteins, 76 
including superantigens, protein A, complement inhibitory protein SCIN, and chemotaxis 77 
inhibitor CHIP (10). A Fur inactivated mutant was shown to be less virulent in a murine 78 
pneumonia model of infection as it was unable to respond adequately to innate immunity (10), 79 
suggesting that in the absence of this key regulatory protein, i.e. in a strain that constitutively 80 
expresses an iron starvation response, virulence is compromised. Under iron limitation, 81 
S. aureus induces the expression of a number of siderophores, siderophore and 82 
xenosiderophore transport systems, as well as heme-related iron sequestration mechanisms 83 
(11, 12). S. aureus has evolved a dedicated transport system for the uptake of 84 
xenosiderophores of the ferric-hydroxymate type consisting of an ATP-binding cassette 85 
transporter encoded by the fhuCBG operon and two lipoprotein receptors FhuD1 and FhuD2 86 
(13, 14). In S. aureus FhuD1 and FhuD2 paralogues possess different specificities for various 87 
hydroxamate siderophores tested (15, 16) and FhuD2 appears to bind exclusively to 88 
hydroxamate xenosiderophores, e.g. ferrichrome, coprogen and aerobactin (17, 18). FhuD2 89 
expression was shown to be induced via reporter gene fusions in the absence of iron or 90 
Fur(18, 19), respectively. 91 
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FhuD2 is part of a vaccine formulation that has been shown to be protective in different 92 
mouse models of infection (15, 16, 20). It has been shown to contribute to bacterial survival in 93 
mouse bacteremia and kidney abscess models (16). Furthermore, gene expression appeared 94 
to be up-regulated approximately 8-fold in bacteria isolated from host kidneys four days after 95 
infection (16), suggesting that the presence of FhuD2 was important for establishing infection 96 
and dissemination of the bacteria already at an early stage. In addition to kidneys, S. aureus 97 
is also known to disseminate into heart, lung and liver tissues as well as into joints and bones 98 
upon intravenous infection in animal models. Previous studies have focused solely on a single 99 
time-point or individual organs when characterizing the expression of fhuD2. However, we 100 
lack information as to the extent of iron deprivation S. aureus undergoes when localizing in 101 
different host organs and throughout the course of its infection. To fill this gap in our 102 
understanding of S. aureus pathogenesis, here, we characterized the temporal and spatial 103 
expression profiles of fhuD2 within the aforementioned mouse organs throughout the infection 104 
process. Interestingly, we found that expression of fhuD2 increased at later stages of 105 
S. aureus infection and that expression levels between organs differed.   106 
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RESULTS 107 
The fhuD2 gene and its regulatory motifs are conserved in all available S. aureus 108 
strains  109 
FhuD1 and FhuD2 are two lipoproteins involved in binding iron (III)-hydroxymates (18). The 110 
genes encoding these lipoproteins are located in different genomic loci (Fig. 1A) and are 111 
distant from each other and from the genes encoding the transmembrane proteins of the fhu 112 
ABC transporter. To evaluate the conservation of the fhuD genes across circulating S. aureus 113 
isolates, we assessed the presence of the respective gene in 4135 available genome 114 
sequences. BLAST analysis showed that fhuD1 was present only in 35.3% (1461/4135) of the 115 
staphylococcal genomes while fhuD2 was conserved in all genomes analyzed. Both fhuD1 116 
and fhuD2 genes showed high identity across different strains (>97%) but showed 117 
significantly lower identities when compared with each other (approximately 42% amino acid 118 
identity and 65% amino acid similarity). These results suggest that while FhuD1 is 119 
dispensable and only in a subset of S. aureus strains analyzed, FhuD2 is present and highly 120 
conserved in all strains, and is likely the main player involved in iron-hydroxymate acquisition.  121 
In order to address whether regulatory elements within the fhuD2 promoter were conserved 122 
among S. aureus isolates, we aligned the 213 bp intergenic sequence between fhuD2 and the 123 
upstream gene (NWMN_2186, an acyl-CoA dehydrogenase-related protein) of 4135 124 
S. aureus isolates and calculated a phylogenetic distance tree (Fig. 1B). The intergenic region 125 
of the fhuD2 gene showed more than 99% identity and clustered into eight clades, defined by 126 
segregating SNPs which were neither present in the predicted promoter nor in regulatory 127 
regions within the promoter sequence (Fig. 1C). Expression of fhuD2 is proposed to be 128 
regulated by the ferric uptake repressor Fur and consistent with this a completely conserved 129 
Fur recognition sequence was identified immediately upstream of the ribosomal binding site of 130 
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fhuD2 (Fig. 1C). This analysis therefore suggested that the regulation of fhuD2 expression is 131 
conserved among various staphylococcal strains.  132 
 133 
Fur controls fhuD2 promoter in an iron availability dependent manner  134 
With the purpose of evaluating the fhuD2 promoter activity in vitro and in vivo we used a 135 
reporter plasmid, pMABA-Par/TA-PfhuD2-lux, with the lux-operon of Photorhabdus luminescens 136 
under the control of the 213 bp-long upstream region of the gene containing the fhuD2 137 
promoter from the S. aureus Newman strain. The plasmid, had been molecularly engineered 138 
to be stably maintained in vitro and in vivo in the absence of a selective antibiotic pressure 139 
(21).  140 
To investigate iron and Fur mediated regulation of fhuD2 in vitro, we constructed a fur 141 
deletion mutant in the Newman strain, transformed both the wild type and the fur mutant 142 
strains with the pMABA-Par/TA-PfhuD2-lux plasmid, and compared bioluminescence emission 143 
during in vitro growth of these strains in the presence or absence of iron over a time course 144 
experiment. The Fur mutant was slightly impaired in its growth in complex media, and while it 145 
grew identically to the wild type strain during early and mid-exponential growth, it only 146 
reached a final OD600 of 6, while the wild type strain reached a OD600 of more than 12 (data 147 
not shown) similarly to what has been previously reported (19). 148 
Newman wild type and fur mutant strains harboring either pMABA-Par/TA-PfhuD2-lux or the 149 
pMABA-Par/TA-lux promoterless control were grown to early-exponential phase (OD600 0.5-150 
0.7) and iron was removed by the addition of dipyridyl to a final concentration of 1 mM. 151 
Samples for bioluminescence determination as well as for mRNA extraction were taken 152 
immediately prior to dipyridyl addition and after 30 and 60 min of incubation. The 153 
bioluminescent signal was normalized to the number of CFU ml-1 present at the time of 154 
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measurement. Bioluminescence was induced 4-fold in the wild-type strain on chelation of iron 155 
(Fig 2A) while constitutively high levels of bioluminescence were measured in the Fur mutant 156 
irrespective of the condition (Fig 2B). The expression levels of fhuD2 mRNA from the 157 
endogenous gene were assessed by qRT-PCR and they increased between 7 to 10-fold 158 
following addition of dipyridyl in the wild-type (Fig 2C). Conversely, fhuD2 mRNA levels in the 159 
Δfur mutant were approximately 5- to 8-fold higher than in the wild type strain in all conditions 160 
(Fig. 2D). These data indicate that Fur represses transcription of fhuD2 in the presence of iron. 161 
In addition, bioluminescence resulting from fhuD2 promoter activity on the episomal reporter 162 
showed a pattern similar to that of the mRNA levels in each strain from the endogenous gene. 163 
The kinetics of induction were slightly faster and the overall increase was slightly higher for 164 
mRNA levels with respect to bioluminescence, however, the regulation of the reporter system 165 
and of the endogenous fhuD2 gene in vitro were aligned, confirming that the fhuD2/luciferase 166 
system was a faithful reporter system in vitro. 167 
 168 
fhuD2 is spatially and temporally regulated during in vivo infection progression  169 
To assess temporal and spatial regulation of fhuD2 in vivo, we infected CD1 mice 170 
intravenously with 107 CFU of exponentially growing S. aureus strain Newman carrying either 171 
the pMABA-Par/TA-PfhuD2-lux reporter or the promoterless control plasmids. The initial 172 
inoculum was prepared from cultures at OD 2.0, a growth phase corresponding to maximal 173 
fhuD2 mRNA expression under in vitro culturing (Fig. S1). In order to follow fhuD2 promoter 174 
expression in vivo in real time and to visualize spatially where the fhuD2 promoter was most 175 
active, we measured the emitted bioluminescence at two, four and seven days post-infection 176 
by means of an IVIS Spectrum-CT® imaging system. A time-dependent increase of the signals 177 
was observed (Fig. 3). No bioluminescence was observed in mice infected with the Newman 178 
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strain transformed with the promoterless control plasmid (data not shown). When mice were 179 
infected with Newman fhuD2 reporter strain (carrying pMABA-Par/TA-PfhuD2-lux), we observed 180 
bioluminescent signals in diverse locations in all animals tested suggesting that bacterial 181 
infection and/or the expression of the reporter lux gene were disseminated over the course of 182 
time (Fig 3A), furthermore the overall bioluminescence increased over time (3B). In addition, 183 
3D-computer tomography (CT) analysis was performed to localize the origin of the 184 
bioluminescent signals in mice more precisely (Fig. 4). Clear bioluminescent signals 185 
manifested at the posterior leg joints already two days after the infection (Fig. 3A) and 3D 186 
reconstruction and CT section analyses confirmed that bacteria had also infected the knee 187 
joint and the femoral bone tissue (Fig. 4 B, D, and F). Four and seven days after infection, 188 
bioluminescence was detected in kidneys (Fig. 3A). Interestingly, CT analysis confirmed that 189 
bioluminescence could be superimposed in some cases onto darker patches observed in 190 
kidneys, likely corresponding to abscesses (Fig. 4B, C and E). This would be consistent with 191 
the fact that bacteria are present together with a large number of neutrophils (22) and fhuD2 192 
is expressed in these structures where bacteria accumulate. Finally, later during the infection, 193 
bioluminescence was observed in the abdominal area corresponding to the liver and heart, as 194 
evidenced by 3D and CT section analyses (Fig. 4H and I). In addition, bioluminescence 195 
persisted in joints and increased in kidneys (Fig. 3A), suggesting that either the bacterial 196 
burden or fhuD2 expression had increased over time.  197 
To determine whether the higher signal intensities in diverse organs and during infection 198 
progression were related to higher bacterial burden, increased fhuD2 expression or both, 199 
heart, lungs, liver and kidneys were collected from infected mice at two, four and seven days 200 
after infection, and CFU/organ, bioluminescence and endogenous fhuD2-specific mRNA were 201 
measured ex vivo. Joint washes were not included in this analysis since the very low amount 202 
 o
n
 O
ctober 10, 2017 by G
lasgow University Library
http://iai.asm
.org/
D
ow
nloaded from
 
 
 
10 
 
of total cellular/bacterial RNA obtained from the samples did not allow us to obtain a 203 
consistent RNA quantification necessary to perform the quantitative real-time PCR at all the 204 
time points.  205 
The determination of CFU numbers demonstrated differential progression of the infection in 206 
the different niches (Fig. 5). Bacteria quickly spread into the various organs and bacterial 207 
burdens averaging between 104 and 106 CFU of organ homogenate were measured two days 208 
after infection. Heart and kidneys exhibited the highest bacterial load per organ with 209 
approximately 106 CFU. While lung and liver both exhibited a bacterial load averaging 210 
between 104 and 105. The lungs of the mice remained with the lowest burden with only a 211 
slight increase in bacterial load (<106 per lung) at 7 days. An approximately 2 log increase in 212 
CFU/organ was observed in liver, heart and kidney organs 7 days after infection. Kidneys 213 
consistently exhibited the highest bacterial load in all mice with >108CFU.  214 
We calculated the relative bioluminescent signal per bacterial cell in the different organs for 215 
each time point and we normalized expression levels to the relative bioluminescent signal per 216 
bacterial cell of the inoculum prior to infection. Expressing the data as fold increase in 217 
bioluminescence relative to the inoculum over time (temporally) for each organ (Fig. 6, A-D) 218 
and for each time point among the different organs (spatially) (Fig. S2), allowed us to obtain 219 
an informative picture of fhuD2 expression in the course of the infection. The specific activity 220 
of the fhuD2 promoter was higher in all organs compared to the inoculum. While we could not 221 
observe bioluminescence in vivo with the IVIS analysis in the lung, bioluminescence was 222 
measured ex vivo in lung homogenates reached over 12-fold increases even at the earliest 223 
time point after infection (2 days) and was maintained throughout the observation period (Fig. 224 
6B). Bioluminescence in kidneys and liver instead was lower (approximately 2-fold) at the 225 
initial stages of infection and augmented with time to a maximum of 16- and 32-fold increases 226 
 o
n
 O
ctober 10, 2017 by G
lasgow University Library
http://iai.asm
.org/
D
ow
nloaded from
 
 
 
11 
 
respectively at 4 days post infection with respect to the initial inoculum (Fig. 6C and D). 227 
Instead approximately 6-fold increase in bioluminescence was observed in the heart at day 228 
two post-infection which increased to over 20-fold at the last time point (Fig. 6A).  229 
We extracted RNA from infected organs at the defined time points and performed quantitative 230 
real-time PCR to measure the fhuD2 mRNA levels of the chromosomal fhuD2 gene during the 231 
course of infection. Expression data were normalized to the mRNA levels of fhuD2 in the 232 
inoculum used to infect mice. Overall, expression of the endogenous fhuD2 gene mRNA, 233 
although not mirroring identically, followed a similar pattern to that observed for the 234 
bioluminescent reporter construct (Fig. 6 E-H and S2 D-F) showing levels 14-fold compared 235 
to the inoculum at all timepoints in the lung, increasing from <10-fold at 2 days to >10-fold 236 
during the course of the infection in the liver and kidneys, and a less evident increase which 237 
did not reach more than 10-fold in the heart. In general, variability of mRNA expression was 238 
lower when compared to variability observed with the bioluminescent reporter construct and 239 
induction kinetics appeared to be faster.  240 
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DISCUSSION 241 
Iron sequestration is an important antimicrobial mechanism exerted by the infected host, 242 
which attempts to limit iron availability to concentrations far below those permitting bacterial 243 
growth (23). Nevertheless, bacteria have developed sophisticated strategies to circumvent 244 
iron limitation during host infection (24, 25), including high affinity iron scavenging 245 
mechanisms. FhuD2, an iron-scavenging lipoprotein, has been shown to play a role in the 246 
early dissemination of S. aureus during infection in animal models (16). Furthermore, 247 
immunization of mice with the FhuD2 recombinant protein consistently confers protection from 248 
S. aureus challenge in diverse models of infection and against a broad range of 249 
staphylococcal isolates (16, 20). Here, we characterize the factors regulating the expression 250 
of this candidate vaccine antigen in vitro and we evaluated the temporal and spatial 251 
expression pattern of fhuD2 in mice infected with S. aureus.  252 
The S. aureus strain used for this study was Newman. This choice was based not only on its 253 
known robust performance in various infection models (26), but also because the main 254 
regulatory motifs in the intergenic region upstream of fhuD2 were conserved in over 4000 255 
strains analyzed, suggesting that regulation of expression of this gene would also be 256 
conserved among different isolates. Evaluation of a fhuD2 reporter construct under in vitro 257 
conditions confirmed that fhuD2 expression was controlled by Fur in an iron-dependent 258 
manner and that the episomal reporter closely reproduced the transcription pattern of the 259 
endogenous fhuD2 gene. We observed a slight temporal delay between the profile of mRNA 260 
steady state levels and the bioluminescent measurement of the reporter where maximal 261 
bioluminescence occurs later than maximal mRNA levels. This is most likely due to 262 
transcriptional and translational delay of the reporter expression. Maximal expression levels of 263 
 o
n
 O
ctober 10, 2017 by G
lasgow University Library
http://iai.asm
.org/
D
ow
nloaded from
 
 
 
13 
 
fhuD2 were observed in the absence of Fur or iron indicating that Fur acts as a repressor to 264 
fhuD2 when it is bound to Fe2+.  265 
Signals from the bioluminescent reporter allowed the monitoring of fhuD2 promoter activity in 266 
vivo after infection but were influenced by the depth of the host organ from the animal’s body 267 
surface, and possibly other factors. We therefore evaluated temporal and spatial expression 268 
profiles of the S. aureus fhuD2 gene by combining in vivo imaging in live mice, with ex vivo 269 
measurements of specific bioluminescence in the organ homogenates in relation to bacterial 270 
load as well as the direct quantification of target gene mRNA as a further control.   271 
The 2D and 3D in vivo imaging of bioluminescence from the reporter strain permitted us to 272 
perform a qualitative evaluation of the exact localization, at the organ and tissue level, of 273 
bacteria expressing the reporter gene in vivo. Bioluminescent signals could be assigned early 274 
after the infection not only at joints but also in the femur in clear areas of infected bone. This 275 
observation was consistent with the known tropism of S. aureus for joints and bones causing 276 
arthritis and osteomyelitis (27). Signals at joints were either steady or increased during 277 
infection progression, suggesting active bacterial replication and/or higher expression levels 278 
of fhuD2 in this environment. As quantitative RT-PCR could not be performed on infected joint 279 
and bone samples due to the presence of relatively few bacteria, tracking expression by 280 
bioluminescent reporter was the only informative approach on gene expression in this niche. 281 
While bacterial load is low, early bioluminescence signals were more easily detected in limbs 282 
likely due to their peripheral location and to the presence of bacteria in a liquid environment. 283 
Similarly, 2D and 3D IVIS analyses allowed the observation of intense signals detected in 284 
kidneys, in which we could associate fhuD2-driven bioluminescence spots and denser areas, 285 
likely representing abscesses. This observation is consistent with reports indicating that 286 
S. aureus finds an iron deficient environment within murine kidney abscesses (28), which 287 
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could trigger induction of fhuD2 gene expression. Interestingly, we frequently noticed that in 288 
some animals one of the two kidneys would not be visible after a certain time during the 3D 289 
reconstruction, and we hypothesize that in these cases the kidney functionality may be 290 
compromised to such an extent that the contrast agent would no longer be able to penetrate 291 
the organ. Finally, the IVIS analysis also allowed confirmation of the induced luciferase 292 
reporter activity in liver tissue while bioluminescence in hearts was only observed once, and 293 
we were unable to detect any bioluminescence in lungs. The difficulty in observing 294 
bioluminescence in these organs, in spite of the detectable CFUs and of fhuD2 promoter 295 
activity detected and quantified by bioluminescence/RNA measured in the homogenized 296 
organs, may be dependent on multiple factors, such as overall low bacterial burden, promoter 297 
activation rate, availability of ATP and oxygen necessary for the bioluminescent reaction, and 298 
depth of the emitting signal but more likely to the lack of accumulation in abscesses.  299 
A different approach was instead necessary to perform quantitative measurements of fhuD2 300 
promoter activation in vivo. This was accomplished by collecting the different organs and 301 
determining the specific bioluminescence per CFU, as well as the fhuD2-specific mRNA 302 
content per CFU, to quantify the fhuD2 promoter activity in the different organs over time and 303 
confirm that the reporter and mRNA content patterns were aligned. Expression of fhuD2 304 
promoter was considerably increased in all in vivo samples with respect to that of the initial 305 
inoculum, and interestingly maximal induction levels measured (>10-fold) were significantly 306 
higher than the maximal in vitro levels either under iron-limiting conditions or in the absence 307 
of the Fur repressor, indicating that level of activation of fhuD2 gene expression in the host 308 
environment cannot be reached under in vitro conditions.   309 
Furthermore, this analysis highlighted that the fhuD2 promoter is differentially regulated in 310 
diverse organs during time. Bioluminescence at day 2 post infection was higher in lungs (>12-311 
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fold) as compared to the other organs analyzed, and was maintained fairly steadily during 312 
infection progression, suggesting that fhuD2 promoter induction is triggered early during 313 
infection of the lung. This is in agreement with recent studies demonstrating that S. aureus 314 
binds considerable amounts of hemoglobin in airways tracts, suggesting that the lung is an 315 
iron-poor environment like the heart (29, 30), which would favor fhuD2 gene activation. In fact, 316 
excess of iron in lungs can contribute to the formation of reactive oxygen species which can 317 
damage lung tissue and iron is therefore complexed by ferritin and transferrin to prevent this 318 
reaction (31-33).  319 
Interestingly, expression levels appeared lower at 2 days post infection in other organs such 320 
as heart, liver and kidneys and generally increased not only with increasing bacterial burden 321 
in the diverse host organs but also with the duration of the infection until reaching a maximum 322 
fold-induction of 10 to 20. Overall, activation of the bioluminescent reporter appeared to 323 
correlate well with the transcription of the endogenous gene, although some differences could 324 
be observed at days four and seven post infection. The observed trend for gradual fhuD2 325 
induction in hearts, livers and kidneys, more evident in BLI than in mRNA analysis, could 326 
suggest that S. aureus does not immediately necessitate the acquisition of iron via the Fhu 327 
system in all organs and that iron availability within different host organs in general becomes 328 
more limiting with progression of the infection. In particular, the highest expression was 329 
observed in the kidney in areas likely to correspond to abscesses, reported to be sites of 330 
calprotectin accumulation and severe cation limitation (34). The liver is considered to be one 331 
of the major iron storage sites within vertebrates (35, 36) and an increased initial availability of 332 
iron in this organ could explain delayed induction of S. aureus fhuD2.  333 
S. aureus has evolved a dedicated iron uptake system that shows high specificity for human 334 
hemoglobin mediated through the hemoglobin receptor IsdB (37). Humanized mice 335 
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expressing human hemoglobin were found to be more susceptible to systemic staphylococcal 336 
infections highlighting S. aureus adaptation to its host (37). In contrast, the FhuD system is 337 
involved in scavenging xenosiderophores present in the host environment (13, 15, 18, 38, 39). 338 
Xenosiderophores are iron scavenging molecules that are can be present in the environment 339 
and are produced by other organisms than S. aureus. The ability of S. aureus to use these 340 
xenosiderophores as an iron source provides the bacterium with a fitness advantage as it is 341 
itself not burdened with their biosynthesis (38). A functioning xenosiderophore uptake system 342 
contributes to staphylococcal survival and dissemination within the murine host (16) indicating 343 
the presence and utilization of these or similar molecules during infection. The stimulus 344 
controlling fhuD2 expression is mediated through Fur and dependent on the available 345 
quantities of iron in the environment (12). As such, expression levels of fhuD2 should 346 
accurately reflect the conditions in which S. aureus was monitored. To date, the majority of 347 
infection studies with S. aureus have been performed using wild-type mice and humanized 348 
mice have mainly focused on immune factors (37). As non-humanized mice were used in our 349 
studies, we cannot fully rule out that the reduced ability of S. aureus to use murine 350 
hemoglobin might influence expression levels of fhuD2 to some extent. Increased virulence of 351 
S. aureus in mice expressing human hemoglobin (37) suggest that S. aureus might be able to 352 
tap into hemoglobin as alternative iron source in some of the organs analyzed. However, the 353 
ability of S. aureus to recover iron from host hemoglobin was also shown to be non-essential 354 
for staphylococcal infection and resulted only in a slight increase of bacterial burden in mouse 355 
livers expressing human hemoglobin compared to wild-type mice (37).  356 
S. aureus employs a multitude of virulence factors in order to establish successful 357 
colonization and infection. However, to date, expression studies of virulence factors during 358 
staphylococcal infection have focused only on single time points and/or a limited number of 359 
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virulence-related genes. Others have focused on changes between colonization states rather 360 
than progression within specific host organs. For example, adhesion factors such as clfA, clfB 361 
and sdrC were shown to be induced during nasal colonization of a cotton rat model(40), while 362 
they appeared to be downregulated during bacteremia (40). Conversely, among other 363 
adhesins, clfA, sdrC and fnbA were expressed more actively in bacteria colonizing murine 364 
hearts (40). However, comparison of expression data in this study is somewhat complicated 365 
by the fact the different animal models were compared to each other (cotton rat and mouse). 366 
The role and induction of SdrC in nasal colonization was recently corroborated in a deep 367 
sequencing study of RNA expression levels of human volunteers colonized with S. aureus 368 
(41). This study further identified that the expression of genes involved in host-immune 369 
evasion such as the staphylococcal complement inhibitor (scn), the chemotaxis inhibitor (chp) 370 
as well as the expression of the secreted toxins such as hemolysins and leukocidins was 371 
induced (41). A study investigating gene expression of S. aureus during acute and chronic 372 
osteomyelitis in a murine model (42) also confirmed the expression of adhesion, immune 373 
evasion and nutrient acquisition mechanisms during prolonged infection. In particular during 374 
the chronic phase of osteomyelitis, S. aureus was shown to gear its gene expression towards 375 
products involved in the stringent response, host tissue degradation and nutrient acquisition 376 
(42). Consistent with our data, S. aureus undergoes increased nutrient and iron deprivation 377 
during prolonged infection. 378 
Monitoring the expression levels of bacterial genes during host infection is challenging and 379 
different methods for analyzing in vivo gene expression have advantages and disadvantages. 380 
Measuring RNA or protein levels in vivo is laborious and can be hampered by low bacterial 381 
RNA concentration as we found with the limb and joint analyses in this study or by the 382 
complexity of the host tissues not permitting precise protein or RNA quantification. In this 383 
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study, the use of a stable episomal reporter plasmid, and a combination of in vivo imaging 384 
and ex vivo quantification of bioluminescence gave accurate and informative information 385 
about fhuD2 expression. Furthermore, the widespread activation of fhuD2 highlights that the 386 
use of iron-regulated promoter reporters for tracking bacterial dissemination in in vivo models 387 
is an interesting approach.  388 
The data that we have here reported demonstrate that fhuD2 is expressed in vivo in multiple 389 
organs and that its expression is spatially and temporally regulated increasing at later 390 
infection stages in some organs. This knowledge further supports the inclusion of FhuD2 in 391 
the recently proposed vaccine formulation (20), since the induction of an effective FhuD2-392 
mediated immune response could result in protection against S. aureus at different stages of 393 
infection.  394 
 395 
  396 
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MATERIALS AND METHODS 397 
Bacterial strains and culture conditions. S. aureus strains used in this study are defined in 398 
Table 1. Strains were grown at 37°C in Tryptic soy broth (TSB, Difco Laboratories) or in 399 
trypticase soy agar (TSA) supplemented with 10 µg ml-1 of chloramphenicol and 5% (v/v) of 400 
sheep blood if required. For the preparation of bacterial challenge inoculum for infection 401 
studies in animals, an aliquot of bacteria (2 ml) frozen in PBS (Phosphate-buffered saline) + 402 
BSA 10% (w/v) + glutamate 10% (w/v) was thawed, inoculated in 48 ml of TSB (starting from 403 
and optical density at 600 nm (OD600) of 0.05) in flasks and incubated at 37°C at 250 rpm until 404 
the OD600 reached 2. Bacteria were washed twice in equal volumes of PBS, collected by 405 
centrifugation for 10 min at 4000 rpm and suspended to 108 CFU ml-1 to reach the necessary 406 
concentration for infection (107 CFU per infectious dose). 407 
 408 
Sequence analysis 409 
Upstream intergenic sequences of the fhuD2 gene including 27 nt of the coding sequence 410 
were extracted from 4135 S. aureus genomes from NCBI databases using BLAST. 411 
Sequences were aligned and a phylogenetic tree calculated using Mega 6 (43). The tree was 412 
then visualized using the EMBL tree of life tool (44) and clusters identified. Representative 413 
strains were selected from each cluster and their intergenic region aligned using CLUSTALW. 414 
 415 
Generation of a fur deletion mutant. For the generation of a clean fur deletion, homologous 416 
fragments of approximately 800 nucleotides upstream and downstream of fur (NWMN_1406) 417 
were amplified using primers NWMN_1406_-796_XbaI_F, NWMN_1406_+6_BamHI_R, 418 
NWMN_1406_+409_BamHI_F and NWMN_1406_+1197_KpnI_R. Amplification products 419 
were fused by PCR, digested with KpnI and SacI and cloned into pBluescript II SK (+) 420 
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creating pBSK-NWMN_1406_del_b. The fused fragment was then amplified from pBSK-421 
NWMN_1406_del_b using primers NWMN_1406_-796_pIMAY_F and 422 
NWMN_1406_+1197_pIMAY_R, digested with KpnI and SacI and cloned into pIMAY (45). 423 
The plasmid was passed through strain RN4220 and then transformed into strain Newman. 424 
Mutant generation was performed as described previously and deletion was verified by PCR 425 
using primers NWMN_1406_-837_F and NWMN_1406_+1228_R and sequencing. 426 
 427 
Kinetics of in vitro fhuD2-promoter driven bioluminescence expression. S. aureus 428 
strains carrying either the control plasmid pMABA-Par/TA-lux (containing the lux operon but 429 
lacking the fhuD2 promoter) or plasmid pMABA-Par/TA-PfhuD2-lux (containing the lux operon 430 
under the control of the fhuD2 promoter) were grown overnight in TSB supplemented with 431 
10 µg ml-1 of chloramphenicol. One ml of overnight culture was washed once in TSB with 432 
chloramphenicol and diluted to a starting OD600 of 0.05. Three aliquots of 200 µl per well per 433 
strain and tested condition were pipetted into the wells of a black, flat-bottom 96-well plate 434 
and the plate incubated at 37°C and 183 rpm in a TECAN Infinite M200pro plate reader. 435 
Bioluminescence intensity and absorbance were recorded throughout the whole experiment. 436 
Where indicated, dipyridyl was added to induce iron dependent promoter expression once 437 
bacteria reached exponential phase growth (OD600≈0.2-0.3 in Tecan). 438 
 439 
Induction of fhuD2 expression by iron chelation. S. aureus strains carrying either the 440 
control plasmid pMABA-Par/TA-lux (containing the lux operon but lacking the fhuD2 promoter) 441 
or plasmid pMABA-Par/TA-PfhuD2-lux (containing the lux operon under the control of the fhuD2 442 
promoter) were grown overnight in TSB supplemented with 10 µg ml-1 of chloramphenicol. 443 
The following day, 50 ml TSB cultures were inoculated to a starting OD600 of 0.05 and grown 444 
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to exponential phase (0.4-0.7) at 37°C and 250 rpm. At this point iron was either chelated out 445 
of the medium by the addition of dipyridyl to a final concentration of 1 mM or the 446 
corresponding volume of ethanol (the solvent of dipyridyl) was added to the control culture. 447 
Samples for absorbance, bioluminescence and CFU determination as well as for RNA 448 
extraction were taken at defined time points. 449 
 450 
CFU determination. 20 µl of S. aureus culture or organ homogenate were diluted directly in 451 
180 µl of ice cold PBS and then 10-fold serially diluted. 10 µl spots of each dilution were 452 
transferred onto TSA plates, dried and incubated overnight at 37°C followed by CFU 453 
determination.  454 
 455 
Mouse infections. Eight to ten-weeks old female CD1 mice (pathogen free) were infected 456 
intravenously with a sub-lethal dose of S. aureus (~ 1×107 CFU per mouse). To assess the 457 
promoter activity in vivo, heart, lung, liver and kidneys were collected for bioluminescence 458 
detection. Each single organ was first homogenized in 2 to 4 ml PBS, and a 100 µl aliquot per 459 
single tissue were transferred into a well of a 96 well black plate (Nunc-U96 PP-05ml BLACK) 460 
and detected at the IVIS100®. Non-infected mice organs served as control for 461 
bioluminescence background. Colony-forming units (CFUs) were determined for each mouse 462 
organ. 463 
 464 
In vivo imaging analysis. 2D in vivo imaging acquisition was performed using an IVIS100® 465 
instrument. After infection with bioluminescent S. aureus strains, mice were anesthetized with 466 
a mixture of oxygen and isofluorane (2.5%) and then transferred to the imaging chamber. 467 
Bioluminescent images are represented using a pseudo-color scale (blue representing the 468 
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least-intense and red representing the most-intense light) that was overlaid on a grey-scale 469 
image to generate a two-dimensional (2D) picture of the distribution of bioluminescent 470 
bacteria in the animal. The acquired image data were saved as 2D arrays containing values 471 
corresponding to the number of photons contained within each pixel. For 3D in vivo imaging 472 
acquisition, an IVIS® Spectrum-CT was utilized. For CT analysis and following 3D 473 
reconstruction animals were treated with contrast agents for soft tissues. In particular, we 474 
used OptiPrep Density Gradient (SIGMA D1556) to highlight urinary tract organs and Exitron 475 
nano 12000 (Miltenyi Biotec) to evidence heart and livers. In both cases, the agents were 476 
administered to the mouse by intravenous injection at a concentration of 400 mg kg-1 and 477 
1800 mg kg-1, respectively. The contrast agents were administered 20 to 30 min before image 478 
acquisition. Image data were analyzed using Living Image 4.4 (Xenogen Corporation). 479 
  480 
Ethics statement. Mice were monitored twice per day in order to evaluate the early signs of 481 
pain and distress according to humane endpoint defined for each model. Animals showing 482 
such conditions were euthanized in accordance with experimental protocols, which were 483 
reviewed and approved by the local Animal Welfare Body and by the Italian Ministry of Health 484 
(protocol number 136/2010-B) for mouse studies. 485 
 486 
Sample collection, determination of bioluminescence in organ homogenates, RNA 487 
extraction and cDNA synthesis. Mouse organs were harvested and homogenized as 488 
described above. 100 µl of this homogenate were transferred to a microtiter plate and the 489 
bioluminescent signal determined using an IVIS100® instrument. The bioluminescent signal 490 
acquired was then related to the CFU/organ of organ homogenate to calculate 491 
bioluminescence per bacterium as measurement of promoter activity. 492 
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For samples for RNA extraction the organs were collected in gentleMACS M tubes (Milteny 493 
Biotech) containing 2 to 4 ml of RNAprotect Bacteria Reagent (QIAGEN, Germany) and 494 
immediately homogenized. Larger cell debris was removed from the homogenized samples 495 
by centrifugation at 100 x g for 5 min and bacteria were thereafter collected by centrifugation 496 
for 10 min at 3200 x g. Bacterial pellets were then either directly processed for RNA extraction 497 
or stored at -80°C. For RNA extraction, the bacterial pellet was resuspended in 1 ml of Trizol 498 
reagent (Ambion) and lysed in a FastPrep®-24 homogenizer (MP Biomedicals) using three 499 
cycles of 60 s at 6.5 m s-2 followed by 5 min incubation on ice after each cycle. RNA was 500 
extracted from the suspension using the Direct-zolTM RNA MiniPrep Kit (Zymo Research) 501 
applying an on-column DNase digestion step using the RNase-free DNase kit (QIAgen) 502 
according to the manufacturer’s instructions. Residual DNA was removed by a second DNase 503 
treatment using RQ1 DNase (Promega) followed by RNA purification using the PureLink kit 504 
(Ambion) according to the manufacturer’s instructions. RNA quality was assessed by gel 505 
electrophoresis and Agilent 2100 Bioanalyzer and absence of contaminating DNA confirmed 506 
by q-PCR. cDNA was synthetized using the SuperScript First-Strand Synthesis System for 507 
RT-PCR (Invitrogen-Life Technologies) according to the manufacturer’s instructions, using 508 
random hexamer primers for reverse transcription (RT) on 300 to 4000 ng of total RNA. 509 
 510 
qRT-PCR. qRT-PCR for in vivo mRNA quantification was performed using Platinum SYBR 511 
Green qPCR SuperMix-UDG (Invitrogen-Life Technologies) using ROX as internal control on 512 
a STRATAGEN Mx3000P QPCR system using the following cycling parameters: 95°C for 513 
10 min; 45 cycles of 95°C for 30 s, 55°C for 30 s and 72°C for 30 s; 95°C for 1 min, 55°C for 514 
30 s and finally 95°C for 30 s. Final data were analyzed using Genex applying inter-plate 515 
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calibration using a control sample. Samples were normalized to the expression levels of gyrB 516 
and relative expression values to the inoculum were calculated.  517 
 518 
Statistical analysis. At least two independent experiments, run under the same conditions, 519 
were performed for all studies. Statistical analysis was performed using Graph Pad Prism 6. 520 
Expression data were reported as logarithm to generate a Gaussian distribution and outliers 521 
determined using the ROUT method (Q=1%). Statistical significance was determined by 522 
ANOVA followed Tukey’s post-test.  523 
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FIGURE LEGENDS 684 
FIG 1 Analysis of the intergenic region upstream of fhuD2. (A) Schematic of fhuD1 and 685 
fhuD2 genomic context and promoter region within strain Newman. (B) Phylogenetic tree of 686 
intergenic sequences upstream of fhuD2, extracted from 4135 S. aureus genomes. Seven 687 
individual clusters representing sequence variants are colored. (C) Multiple sequence 688 
alignment of representative sequence variants from each cluster. The start site of the coding 689 
sequence is highlighted in blue, while predicted regulatory elements such as the Fur-binding 690 
motif and -10 and -35 recognition sequences are highlighted in green and orange, 691 
respectively. 692 
 693 
FIG 2 Fur-dependent iron regulation of fhuD2. S. aureus Newman strain (NM) and its Fur 694 
mutant (Δfur) harboring the fhuD2 reporter plasmid were grown as 50 ml TSB cultures to 695 
early/mid exponential phase and iron starvation was induced by adding dipyridyl to a final 696 
concentration of 1 mM (DIP) or by adding an identical volume of the solvent (ethanol) to the 697 
control culture (TSB). (A&B) Bioluminescence data were normalized using the CFUs of the 698 
respective time points and are represented as expression levels relative to the wild-type TSB 699 
culture prior to induction. (C&D) mRNA expression levels were determined for the 700 
endogenous fhuD2 gene and are represented as expression levels relative to the wild-type 701 
TSB culture prior to induction. Data shown represent triplicate measurements from two 702 
independent biological repeats. Statistical analysis was performed using ANOVA followed by 703 
Tukey’s post-test. ** p<0.01, ***p<0.001, **** p<0.0001, ns not significant. 704 
 705 
FIG 3 Visualization of fhuD2 expression in vivo. CD1 mice were infected with strain 706 
Newman carrying the fhuD2 reporter plasmid and monitored daily by using the IVIS100® 707 
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imaging system. (A) Representative 2D pictures of the distribution of bioluminescent signals 708 
of mice acquired in a dorsal or ventral position at 2, 4 and 7 days post-intravenous challenge 709 
with the bioluminescent Newman strain. (B) Quantification of bioluminescence/mouse through 710 
ROI analysis. Values reported at day 0, are from non-infected mice. 711 
 712 
FIG 4 Localization of bioluminescence by 3D and CT analysis of mice infected with 713 
S. aureus strain Newman carrying the fhuD2 reporter plasmid. Images were collected 7 days 714 
post intravenous challenge. (A) Representative ventral 2D and (B) 3D reconstruction and (C-F) 715 
TAC analysis evidence that bioluminescence signals arise from bone, knee and kidneys sites 716 
and (G) representative dorsal 2D and (H) 3D reconstruction or (I) TAC analysis evidence 717 
bioluminescent signals in liver and in heart. Legend: K: kidney; B: bladder; H: heart; L: lung; Li: 718 
liver. For TAC analysis, we reported sagittal transversal sections. 719 
 720 
FIG 5 Progression of S. aureus infection in various host organs. CD1 mice were infected 721 
with 107 CFU of S. aureus strain Newman. Organs (A, heart; B, Lungs; C, Livers and D, 722 
Kidneys) were collected at the defined time points, homogenized and CFU per ml of 723 
homogenized organ determined. 724 
 725 
FIG 6 Quantification of fhuD2 promoter activity in infected mouse organs. (A-D) 726 
Development of bioluminescence levels in the indicated organs throughout a 7-day infection 727 
time course. fhuD2 promoter activity was determined as bioluminescence per CFU and fold 728 
changes were calculated as compared to the inoculum. (E-H) fhuD2 mRNA levels:  fhuD2 729 
promoter activity from the endogenous fhuD2 gene was determined by qRT-PCR and fold 730 
changes were calculated relative to the inoculum before infection. Each symbol corresponds 731 
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to an organ of a single animal. Numbers depicted above the time points represent the mean 732 
of the respective dataset. Statistical analysis was performed on logarithmic data using 733 
ANOVA followed by Tukey’s post-test and refers to the inoculum if not otherwise indicated. 734 
*p<0.05, **p<0.01, ***p<0.001. Data plotted represent the mean of each group. 735 
 736 
  737 
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TABLES 738 
 739 
Table 1 Strains and plasmids 740 
 741 
Strains or plasmid Relevant characteristics Source or 
reference 
S. aureus strains   
Newman MSSA, clumping factor overproducer, UK, CC8, CPS 
5 
(26) 
RN4220 hsdR
-
, restriction negative strain used for preparing 
plasmids 
(46) 
E. coli strains   
DH5α supE44 lacU169 (w80lacZDM15) hsdR17 recA1 
endA1 gyrA96 thi-1 relA1 
Bethesda Research 
Laboratories 
Plasmids   
pOS1 S. aureus ORI for Gram-positive strains; pBR322 
plasmid replication in Gram-negative bacteria; Amp
R
 
and Cm
R
 
(47) 
pBluescript II SK (+) Standard cloning vector, Amp
R
 Stratagene 
pIMAY E. coli/S. aureus shuttle vector, temperature 
sensitive, Cm
R
 
(45) 
pMABA-Par/TA-lux pOS1 carrying luxABCDE, toxin/antitoxin (ɛ/ζ) + par 
system 
(21) 
pMABA-Par/TA-PfhuD2-lux pOS1 carrying luxABCDE under the control of the 
fhuD2 promoter, toxin/antitoxin (ɛ/ζ) + par system 
(21)” 
 742 
Table 2 Primers  743 
Primer name Sequence (5’3’) Application 
Sa_16s_+332_F GAGACACGGTCCAGACTCCT qRT-PCR 
Sa_16s_+437_R ACGATCCGAAGACCTTCATC “ 
Sa_gyrB_+238_F ACGGATAACGGACGTGGTAT “ 
Sa_gyrB_+339_R GCCAAATTTACCACCAGCAT “ 
Sa_fhuD2_+480_F AGAAACAACTGCTAAAGACGGT “ 
Sa_fhuD2_+594_R ACCCCAGTTATCGCCGTAA “ 
NWMN_1406_-796_XbaI_F GGCCGCTCTAGACCTAAACTCATGCAACCTAGAC
C 
fur deletion 
NWMN_1406_+6_BamHI_R ACCATGGGATCCTTCCAACGATGTCCACTCC “ 
NWMN_1406_+409_BamHI_F TTGGAAGGATCCCATGGTGTGTGTGAAACGTG “ 
NWMN_1406_+1197_KpnI_R GAATTGGGTACCGTTTGCCTTTACACCATTTTG “ 
NWMN_1406_-796_pIMAY_F CGACTCACTATAGGGCGAATTGGAGCTCCCTAAA
CTCATGCAACCTAGACC 
“ 
NWMN_1406_+1197_pIMAY_R CCTCACTAAAGGGAACAAAAGCTGGGTACCGTTT
GCCTTTACACCATTTTG 
“ 
NWMN_1406_-837_F CAGCACAATCTATAATTTGTTCGGC “ 
NWMN_1406_+1228_R GTAACGTATGTGGCGTTAACGTC “ 
 744 
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AfhuD1 consensus             -35                   -10       Fur box                 RBS 
5’TACTGATGTGTATTACTAACAGGCGTTGACTAATTCTTTTAATATTTTATAATTGAAAATGAATATCAATTGAAAAACAAAAGGATGATATTATG
fhuD2 consensus            -35                    -10                  Fur box      RBS        
5’TAAAAAAATAAATAACACTAGCTATTGTAAATGTATATGCAATCTTGTATAATTTTGGAATAATTGATAATCATTTTCAATAGGAGGAAATTATG
fhuD2
NWMN
_2184NWMN_2183 NWMN_2186
fhuD1NWMN_1930 NWMN_1932
C               -35       -10            Fur-box             Start
Newman    TAAAAAA-TAAATAACACTAGCTATTGTAAATGTATATGCAATCTTGTATAATTTTTGAATGATTGATAATCATTTTCAATAGGAGGAAATTATG
FPR3757   TAAAAAA-TAAATAACACTAGCTATTGTAAATGTATATGCAATCTTGTATAATTTTTGAATGATTGATAATCATTTTCAATAGGAGGAAATTATG
EMRSA-15   TAAAAAAATAAATAACACTAGCTATTGTAAATGTATATGCAATCTTGTATAATTTTGGAATGATTGATAATCATTTTCAATAGGAGGAAATTATG
S130    TAAAAAAATAAATAACACTAGCTATTGTAAATGTATATGCAATCTTGTATAATTTTGGAATGATTGATAATCATTTTCAATAGGAGGAAATTATG
EMRSA16   TAAAAAAATAAATAACACTAGCTATTGTAAATGTATATGCAATCTTGTATAATTTTGGAATAATTGATAATCATTTTCAATAGGAGGAAATTATG
M013   TAAAAAA-TAAATAACACTAGCTATTGTAAATGTATATGCAATCTTGTATAATTTTGGAATAATTGATAATCATTTTCAATAGGAGGAAATTATG
MW2    TAAAAAAATAAATAGCACTAGCTATTGTAAATGTATATGCAATCTTGTATAATTTTGGAATAATTGATAATCATTTTCAATAGGAGGAAATTATG
ED98    TAAAAAAATAAATAGCACTAGCTATTGTAAATGTATATGCAATCTTGTATAATTTTGGAATAATTGATAATCATTTTCAATAGGAGGAAATTATG
Mu50    TAAAAAAATAAATAGCACTAGCTATTGTAAATGTATATGCAATCTTGTATAATTTTGGAATAATTGATAATCATTTTCAATAGGAGGAAATTATGMu50Ω    TAAAAAAATAAATAGCACTAGCTATTGTAAATGTATATGCAATCTTGTATAATTTTGGAATAATTGATAATCATTTTCAATAGGAGGAAATTATG
N315    TAAAAAAATAAATAGCACTAGCTATTGTAAATGTATATGCAATCTTGTATAATTTTGGAATAATTGATAATCATTTTCAATAGGAGGAAATTATG
Consensus   TAAAAAAATAAATAACACTAGCTATTGTAAATGTATATGCAATCTTGTATAATTTTGGAATAATTGATAATCATTTTCAATAGGAGGAAATTATG
B
I
II
III
IV
V
VI
VII
Mu50
Newman
FPR3757
EMRSA16
EMRSA-15
S130
M013
MW2
N315
ED98
Mu50Ω  on
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